According to new research, M&As within the life science industry reached a high last year and is expected to continue its growth in 2020.
List view / Grid view
Mergers & Acquisitions
Filter the results
According to Eli Lilly, the company will acquire Dermira in an all-cash transaction for $1.1 billion, at a rate of $18.75 per share.
Xyphos Biosciences will become a wholly owned subsidiary of Astellas Pharma following an acquisition made by the latter company.
Mergers and acquisitions in any market can define the landscape for its players. In this article, Emma Danks of Taylor Wessing reflects on recent M&A activity in the biopharmaceutical industry, highlighting influencing trends and what this might mean for the future.
The CMA has cleared the anticipated purchase of gene therapy company Spark Therapeutics by pharmaceutical company Roche Holdings.
Sanofi has announced it is to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 billion.
Astellas has announced that it will be acquiring Audentes Therapeutics at a total cost of $3 billion.
The M&A between Novartis and The Medicines Company will add inclisiran, the potentially first-in-class treatment to reduce cholesterol, to the former’s pipeline.
After regulatory approval, Bristol-Myers Squibb has announced its successful acquisition of Celgene, completing the merger.
Loss of manufacturing capability as a result of regulatory non-compliance can have a devastating impact on biopharma or medical device manufacturers. In this article, Jenny Yu shares real-life examples from the industry and highlights the downstream effects of these business interruptions.
Research has found that North America had the most strategic partnerships in the pharma industry from 2014 to 2019.
Large-value deals are a new strategy for stakeholders to capitalise on the strengths of other companies and to overcome barriers to financial success.
The British Pharmacopoeia and United States Pharmacopeia partnership is to be formalised to strengthen the quality of medicines and public health.
A treatment for anaemia associated with chronic kidney disease in dialysis patients has been approved in Japan.